Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 20/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2507349 | 0.99 | CXCR4 (0.83) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| SCHEMBL29823655 | 0.99 | CXCR4 (0.83) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| SCHEMBL28435964 | 0.93 | CXCR4 (0.73) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| SCHEMBL29859912 | 0.93 | CXCR4 (0.73) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| Bromide SCHEMBL4544117 | 0.91 | CXCR4 (0.98) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| SCHEMBL1878773 | 0.90 | CXCR4 (1.00) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| SCHEMBL29823518 | 0.90 | CXCR4 (1.00) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| Bromide SCHEMBL5140263 | 0.89 | CXCR4 (0.83) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| SCHEMBL13909537 | 0.89 | CXCR4 (0.83) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| SCHEMBL13909797 | 0.88 | CXCR4 (0.79) | CXCR4CYP2D6CYP3A4CHRM2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935692-B2 | Methods to mobilize progenitor/stem cells | GENZYME CORPORATION (US) | 2011-05-03 | — | — | US | claimed |
| US-20150246019-A1 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | GENZYME CORP (US) | 2015-09-03 | — | — | US | disclosed |
| US-20130273009-A1 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | GENZYME CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-20110129448-A1 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | GENZYME CORPORATION (US) | 2011-06-02 | — | — | US | disclosed |
| US-7935692-B2 | Methods to mobilize progenitor/stem cells | GENZYME CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7897590-B2 | administering compounds which bind to the chemokine receptors, such as 1,1'-[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane, optionally with colony stimulating factors, to effect regeneration of dead myocardium ; FDA Orange book listed patent for Plerixafor | GENZYME CORPORATION (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100178271-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-7629337-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20060264434-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED INC. (CA) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264434-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | CHRM2 291/4885CXCR4 2/4885CYP2D6 934/4885 |
| US-20110129448-A1 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | CXCR4, CXCL12, CCR2 | CHRM2 607/4885CXCR4 1/4885CYP2D6 4259/4885 |
| US-20130273009-A1 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | CXCL12, CXCR4, CXCR1 | CHRM2 1642/4885CXCR4 2/4885CYP2D6 4722/4885 |
| US-20150246019-A1 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | CXCR4, CXCL12, CCR2 | CHRM2 607/4885CXCR4 1/4885CYP2D6 4259/4885 |
| US-20100178271-A1 | Combination Therapy | CXCL12, CSF3R, CXCR4 | CHRM2 3149/4885CXCR4 3/4885CYP2D6 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.